Skip to search formSkip to main contentSkip to account menu

crenolanib

Known as: [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine, PDGFR Inhibitor CP-868596, PDGFR inhibitor CP-868,596 
An orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (3)

Antineoplastic AgentsBenzimidazolesPiperidines

Narrower (1)

CP-868,596
Inhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPlatelet-Derived Growth Factor ReceptorPositive Regulation of Apoptosis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Neue AML-Risikodefinition hat Kinderleben gerettet
Charakteristika der „neuen“ FLT-3-Inhibitoren Crenolanib ist ein starker Typ-1-Inhibitor, der gegen FLT3-ITD und FLT3-D835… 
2018
2018
Abstract 805: NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML
FLT3, KIT and CSF1R are members of the class III receptor tyrosine kinase family, characterized by an autoinhibitory… 
2017
2017
Azacitidine combined with crenolanib abrogates niche protection and expansion of residual leukemic stem cells (LSC) in FLT3-ITD+ acute myeloid leukemia (AML) with concurrent gene mutations in NPM1…
Tyrosine kinase inhibitors (TKI) have limited impact as single agents in FLT3-ITD+ acute myeloid leukemia (AML), failing to… 
2016
2016
Novel Agent Active in FLT3-Positive Acute Myeloid Leukemia
Crenolanib, a type I pan FLT3 inhibitor, had activity in a group of patients with FLT3-positive acute myeloid leukemia (AML… 
2014
2014
Mechanisms of Resistance to the Fms-like Tyrosine Kinase 3 Inhibitor Crenolanib
2013
2013
Therapeutic agent Crenolanib mutant flt3 proliferative disorder (crenolanib)
The present invention is constitutively active and use of Crenolanib pharmaceutically acceptable salt form in the treatment of… 
2013
2013
I crenolanib for the treatment of proliferative disorders that have mutated FLT3
A composition comprising a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof for use… 
2013
2013
Crenolanib for the treatment of proliferative disorders mutant flt3
2013
2013
Crenolanib for treating flt3 mutated proliferative disorders
2013
2013
Abstract P6-12-15: Preclinical testing of a novel platelet derived growth factor receptor alpha (PDGFRa) inhibitor in inflammatory breast cancer
Inflammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer and carries a guarded prognosis. IBC…